Alnylam Pharmaceuticals (ALNY) PT Raised to $470 at BMO Capital

BMO Capital analyst Kostas Biliouris raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $470.00 (from $450.00) while maintaining a Outperform rating.

The analyst commented: "Following Zilebesiran's PhII readout here, investor inbound revolved around Zilebesiran's (1) Efficacy compared to key competitors Lorundrostat/Baxdrostat; (2) CVOT results, and potential impact from low compliance in diuretics use (given lower Zilebesiran efficacy without diuretics in PhII); (3) Commercial potential. Overall, we think the 9.2mmHg SBP lowering in KARDIA-3 subgroup positions Zilebesiran well for a successful CVOT, while Zilebesiran's MoA, Q6M regimen, Part B reimbursement, and commercialization by ALNY/RHHBY set Zilebesiran up for a promising commercial trajectory (cons≈$3B risk-unadjusted sales in 2035). PT to $470, remaining OP."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Critical One Energy closes second tranche of flow-through placement